Samsung Biologics is moving into peptide ingredient manufacturing by planning to acquire Swiss CDMO PolyPeptide for $1.8 billion in cash. The transaction, announced Monday, would give Samsung Biologics a platform in peptide manufacturing at a time when biologics-only strategies are broadening across adjacent modalities. For PolyPeptide, the deal provides a liquidity event and potential scale benefits tied to the larger Samsung CDMO footprint. The consideration is set at $1.8 billion, and the announcement marks a notable geographic and capability expansion beyond Samsung’s core biologics process expertise. CDMOs watching the move will likely focus on how Samsung integrates peptide capabilities into its broader manufacturing network and customer offering.